India's Health Ministry commendably expanded Schedule H2 drug regulations, shifting from revenue-based to risk-based control. This framework, requiring QR codes on therapeutic classes, aims to combat counterfeits, track batches, and address global quality concerns. While offering potential to improve India's pharmaceutical reputation and fight antimicrobial resistance, the system faces significant implementation hurdles. These include a state-managed real-time database, fostering verification habits, supporting MSME manufacturers, and ensuring robust digital governance for sensitive data. Ultimately, its effectiveness hinges on meticulous implementation.